ReviewAsian Pacific journal of cancer prevention : APJCP2025
Innovations in Oncology Diagnostics: Genetic Research and Liquid Biopsy as Tools of Personalised Medicine.
Review in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to analyze contemporary approaches to cancer diagnosis and treatment using liquid biopsy, with a particular focus on the efficacy of oncogenic biomarker detection in various biological fluids. MATERIALS AND
methodsThis study examined scientific literature from the last five years on the use of liquid biopsy in oncology, focusing on tumour marker detection in blood, plasma, saliva, and urine, along with their analytical significance and clinical implications.
resultsTumour-derived circulating nucleic acids, circulating tumour cells, and secretory vesicles isolated from biological fluids were shown to be highly informative. These enabled the detection of mutations in key oncogenic markers (AR, KRAS, EGFR, PIK3CA, PTEN, P53), quantification of regulatory RNAs (BCAR4, UCA1, H19, miR-21, miR-146a-5p, miR-181a), and assessment of translational levels of proteins such as Cfh, Muc1, Bst2, Er, and Ccne1. Transcriptomic analysis provided insights into T-lymphocyte activity, tumour resistance to gefitinib and tyrosine kinase inhibitors, and the suppression of tumour progression. The expression of proteoglycans isolated from exosomes was identified as a marker of early-stage pancreatic cancer. The titre of CTCs enabled the prediction of recurrence in 64% of patients with lung carcinoma and 100% of post-surgical cases of colorectal cancer, facilitating hormone therapy adjustments in prostate cancer patients. Mutations in the EGFR gene, amplified from persistent deoxyribonucleic acid, were used to adjust chemotherapy regimens throughout the course of treatment.
conclusionThe analysis of material obtained from the biological fluids of oncology patients enabled disease prognosis, risk assessment of progression, and the determination of optimal approaches to personalised therapy, ultimately improving treatment efficacy. The collected data may serve as a foundation for clinically valuable laboratory studies and practical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.